This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Corcept Therapeutics Incorporated. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Lawrence Lu
Introduction
Lawrence Lu is a notable inventor based in Menlo Park, California. He has made significant contributions to the field of cancer treatment through his innovative patent. His work focuses on improving the prognosis and survival rates of cancer patients by utilizing a unique method involving glucocorticoid receptor antagonists.
Latest Patents
Lawrence Lu holds a patent titled "Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist." This patent describes methods for treating cancer patients who have a neutrophil-to-lymphocyte ratio (NLR) greater than 3. The methods involve administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to effectively reduce the patient's NLR. The GRA can be orally administered and may include compounds such as relacorilant or exicorilant. The treatment methods aim to enhance cancer therapies, improve patient prognosis, and provide beneficial clinical effects.
Career Highlights
Lawrence Lu is associated with Corcept Therapeutics Incorporated, where he continues to advance research in cancer treatment. His innovative approach has the potential to significantly impact the effectiveness of various cancer therapies, including chemotherapy, immunotherapy, and radiation therapy.
Collaborations
Some of his notable coworkers include Andrew Greenstein and Joseph Custodio. Their collaborative efforts contribute to the ongoing research and development of effective cancer treatments.
Conclusion
Lawrence Lu's innovative work in cancer treatment exemplifies the importance of research and development in improving patient outcomes. His patent on normalizing the neutrophil-to-lymphocyte ratio represents a significant advancement in the field.